CRIS Current Research Information System

PERRONE, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.045
AS - Asia 1.493
EU - Europa 1.268
AF - Africa 123
SA - Sud America 83
OC - Oceania 1
Totale 5.013
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.026
VN - Vietnam 489
CN - Cina 395
SG - Singapore 340
GB - Regno Unito 304
SE - Svezia 197
IT - Italia 172
DE - Germania 156
FR - Francia 86
HK - Hong Kong 76
IN - India 66
RU - Federazione Russa 65
UA - Ucraina 62
NL - Olanda 57
BR - Brasile 55
IE - Irlanda 45
TG - Togo 35
CH - Svizzera 31
ZA - Sudafrica 30
CI - Costa d'Avorio 26
FI - Finlandia 25
JP - Giappone 21
EE - Estonia 18
PH - Filippine 16
BG - Bulgaria 14
CA - Canada 14
KR - Corea 14
BE - Belgio 13
AR - Argentina 12
BD - Bangladesh 12
SC - Seychelles 12
TH - Thailandia 11
JO - Giordania 10
TR - Turchia 10
NG - Nigeria 9
IR - Iran 8
CO - Colombia 5
LB - Libano 5
PL - Polonia 5
TW - Taiwan 5
AT - Austria 4
EC - Ecuador 4
CL - Cile 3
DZ - Algeria 3
ES - Italia 3
IL - Israele 3
IQ - Iraq 3
LT - Lituania 3
MA - Marocco 3
RO - Romania 3
VE - Venezuela 3
EG - Egitto 2
GR - Grecia 2
KE - Kenya 2
NP - Nepal 2
PK - Pakistan 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
MX - Messico 1
PA - Panama 1
PY - Paraguay 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 5.013
Salva come PNG Salva come JPEG
Città #
Southend 268
Ashburn 259
Singapore 231
Chandler 218
Fairfield 183
Dong Ket 130
Woodbridge 106
Ann Arbor 83
Seattle 82
Houston 78
Wilmington 77
San Jose 75
Beijing 74
Cambridge 72
Hong Kong 72
Ho Chi Minh City 67
Hanoi 63
Princeton 59
Santa Clara 47
Dublin 45
Bologna 42
New York 41
Jacksonville 40
Boardman 38
Lomé 35
Nanjing 35
Hefei 31
Los Angeles 27
Abidjan 26
Bern 26
Bremen 25
Westminster 25
Helsinki 24
Padova 24
Lauterbourg 20
Shenyang 19
Tokyo 19
Jinan 18
Buffalo 16
Changsha 15
Berlin 14
Frankfurt am Main 14
Sofia 14
Turin 14
Brussels 13
Hebei 13
São Paulo 13
Haiphong 12
Saint Petersburg 12
Redwood City 11
Amman 10
Seoul 10
Abeokuta 9
Da Nang 9
Mülheim 9
Nanchang 9
Council Bluffs 8
Verona 8
Dallas 7
Falkenstein 7
Medford 7
San Diego 7
Tianjin 7
Washington 7
Guangzhou 6
Hangzhou 6
Jiaxing 6
London 6
Milan 6
Monmouth Junction 6
Montreal 6
Norwalk 6
Orem 6
Paris 6
Zhengzhou 6
Brooklyn 5
Hải Dương 5
Mahé 5
Munich 5
The Dalles 5
Wuhan 5
Amsterdam 4
Ardabil 4
Bangkok 4
Can Tho 4
Chicago 4
Crevalcore 4
Dearborn 4
Denver 4
Falls Church 4
Johannesburg 4
Lanzhou 4
Naples 4
Pune 4
Redmond 4
Redondo Beach 4
Rome 4
Roubaix 4
Shanghai 4
Winnipeg 4
Totale 3.251
Salva come PNG Salva come JPEG
Nome #
Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. 344
A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. 311
Prediction of response to primary therapy with thalidomide-dexamethasone (thal-dex) for newly diagnosed multiple myeloma by gene expression profiling (gep) 251
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 236
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 224
Ascorbic acid inhibits antitumor activity of bortezomib in vivo 203
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 203
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 200
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. 197
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. 197
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation 197
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 195
Complete remission upon bortezomib-dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation. 195
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 186
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 180
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 179
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 178
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 175
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 174
HIF-1a INHIBITION PROMOTES CELL CYCLE ARREST IN MULTIPLE MYELOMA 168
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 166
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 158
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 155
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treatedwith zoledronic acid and thalidomide-dexamethasone. 155
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 154
Proteasome inhibitors: Bortezomib in multiple myeloma 93
Totale 5.074
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021206 0 0 0 0 0 0 0 0 0 0 0 206
2021/2022606 96 15 32 41 51 34 7 30 20 65 107 108
2022/2023816 88 142 34 130 42 69 24 34 112 25 54 62
2023/2024207 10 32 14 20 25 65 11 5 2 8 6 9
2024/2025530 10 57 41 39 76 34 45 31 3 76 7 111
2025/20261.316 132 91 101 87 168 80 109 30 307 111 57 43
Totale 5.074